We next examined whether current first-line therapies for DKD—renin-angiotensin system (RAS) blockade and sodium-dependent glucose transporter 2 (SGLT2) inhibition—modulate podocyte expression of FGF4 and FGFR1. This evidence concerns the gene FGFR1 and diabetic kidney disease.